Development of an Optimized Adjuvanted TB Vaccine

NIH RePORTER · NIH · N01 · $358,674 · view on reporter.nih.gov ↗

Abstract

To identify the optimal adjuvant for recombinant vaccines and inactivated flu vaccines, and to identify correlates of protection against infection or disease, experimental vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

Key facts

NIH application ID: 11196784
Project number: 75N93019C00045-P00023-9999-4
Recipient: UNIVERSITY OF MONTANA
Principal Investigator: JAY EVANS
Activity code: N01
Funding institute: NIH
Fiscal year: 2024
Award amount: $358,674
Award type: —
Project period: 2021-09-30 → 2025-09-30